A Study of Lorigerlimab in Participants With Advanced Solid Tumors (NCT06730347)
A Phase 2 Multicohort Study to Evaluate Lorigerlimab in Participants With Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 80 participants will be enrolled. The study will assess the efficacy and safety of lorigerlimab in participants with PROC or CCGC. Participants will receive lorigerlimab by intravenous (IV) infusion on Day 1 of every 21-day treatment cycle. Treatment cycles will continue until progression of cancer, unacceptable side effects, withdrawal of consent by the participant, or the study ends. Participants will be monitored closely for side effects by physical exam and routine laboratory tests every cycle. Tumor status will be checked approximately every 9 weeks for the first year, then every 12 weeks for the duration of treatment. Participants will have a safety followup performed within 30 days after treatment discontinuation. Participants who discontinue study treatment for reasons other than progression of cancer, will continue CA-125 and tumor assessments every 12 weeks. Participants who discontinue study treatment for progression of cancer will enter the 6-month survival follow up portion of the study.
Who can join: Review the eligibility criteria below.
Location: UCLA — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- UCLA — Los Angeles, California
- Ochsner MD Anderson Cancer Center — New Orleans, Louisiana
- START Midwest — Grand Rapids, Michigan
- West Penn Allegheny Health — Pittsburgh, Pennsylvania
- The University of Texas MD Anderson Cancer Center, Gynecologic Oncology Center — Houston, Texas
- START San Antonio — San Antonio, Texas
- Wisconsin Institute Medical Research- UW Cancer Connect — Madison, Wisconsin
- Princess Margaret Cancer Center — Toronto, Ontario
- McGill University — Montreal, Quebec
- National Cancer Center — Goyang-si, Gyeonggi-do
- Seoul National University Hospital Bundang Hospital — Seongnam-si, Gyeonnggi-Do
- Yonsei University Health System Severance Hospital — Seoul,
- Gangnam Severance Hospital — Seoul,
- Korea University Guro Hospital — Seoul,
- Seoul National University Hospital — Seoul,
- Samsung Medical Center — Seoul,
📞 Contact the Study Coordinator
Phone: (301) 251-5172
Email: info@macrogenics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Platinum-resistant Ovarian Cancer
- Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) — Phoenix, Arizona
- Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer — Anchorage, Alaska
- A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors — Little Rock, Arkansas
- A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer — El Segundo, California
- Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer — Boston, Massachusetts
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) — Mobile, Alabama
Explore by condition: All Platinum-resistant Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.